Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page
- Check2 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' to the content and included a new Resources link to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision stamp updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page revision was updated from v3.4.1 to v3.4.2. No user-facing content or functionality was altered.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page shows a minor version bump from v3.4.0 to v3.4.1, a routine update with no visible changes to study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check60 days agoChange DetectedShow glossary option added and QC-related labels updated to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. The earlier entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed.SummaryDifference0.2%

Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.